¿¬¼ÓÇ÷´çÃøÁ¤½Ã½ºÅÛ(CGMS) ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Çâ, ¿¹Ãø : ÄÄÆ÷³ÍÆ®, Àα¸Åë°è, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°(2025-2033³â)
Continuous Glucose Monitoring Systems Market Size, Share, Trends and Forecast by Component, Demographics, End User, and Region, 2025-2033
»óǰÄÚµå : 1722845
¸®¼­Ä¡»ç : IMARC Group
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 143 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,999 £Ü 4,130,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 3,999 £Ü 5,507,000
PDF & Excel (5 User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,999 £Ü 6,884,000
PDF & Excel (Corporate License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è ¿¬¼ÓÇ÷´çÃøÁ¤½Ã½ºÅÛ(CGMS) ½ÃÀå ±Ô¸ð´Â 2024³â 70¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÇâÈÄ IMARC GroupÀº ÀÌ ½ÃÀåÀÌ 2033³â±îÁö 109¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇϰí, 2025-2033³â 4.75%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ÇöÀç ºÏ¹Ì°¡ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖÀ¸¸ç, 2024³â¿¡´Â 38.7% ÀÌ»ó ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, CGM ±â±â¿¡ ´ëÇÑ ÀÎ½Ä ¹× äÅà Áõ°¡, ´ç´¢º´ À¯º´·ü Áõ°¡, CGM ±â±âÀÇ ±â¼ú ¹ßÀü, ¿¹¹æÀû °Ç°­°ü¸®·ÎÀÇ Áö¼ÓÀûÀÎ Àüȯ µîÀÌ ¿¬¼ÓÇ÷´çÃøÁ¤½Ã½ºÅÛ(CGMS) ½ÃÀå Á¡À¯À²À» ³ôÀÌ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ °ÍÀÔ´Ï´Ù. ½ÃÀå Á¡À¯À²À» ³ôÀÌ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

¿¬¼ÓÇ÷´çÃøÁ¤½Ã½ºÅÛ(CGMS)Àº Ç÷´ç ¼öÄ¡¸¦ ÀÚµ¿À¸·Î ÃßÀûÇÏ´Â ±â¼úÀûÀ¸·Î Áøº¸µÈ ÀåÄ¡ÀÔ´Ï´Ù. Æ®·£½º¹ÌÅÍ ÀÏüÇü ¼¾¼­·Î ±¸¼ºµÇ¾î °æÇÇ ¶Ç´Â ÇÇÇÏ °æ·Î·Î ÀÛµ¿ÇÏ¸ç °£Áú¾× ³» Æ÷µµ´ç ³óµµ¸¦ Áö¼ÓÀûÀ¸·Î ÃøÁ¤ÇÕ´Ï´Ù. Æ®·£½º¹ÌÅÍ´Â ±× Á¤º¸¸¦ ÀǺ¹¿¡ Âø¿ëÇÒ ¼ö ÀÖ´Â ¹«¼± ¸ð´ÏÅÍ·Î Àü¼ÛÇÕ´Ï´Ù. ¿¬¼ÓÇ÷´çÃøÁ¤½Ã½ºÅÛ(CGMS)Àº ´ç´¢º´¿¡ ´ëÇÑ ¿ÏÀüÇÑ ÇÁ·ÎÆÄÀÏÀ» Á¦°øÇϰí, Ç÷´çÀÌ ³ô°Å³ª ³·À» ¶§ °æ°íÇϰí, ÆÐÅÏÀ» °¨ÁöÇϰí, ½Åü Ȱµ¿, ¾à¹° ¼±ÅÃ, ½Ä»ç·®, ½ºÆ®·¹½º¿¡ ´ëÇÑ È¯ÀÚÀÇ ÅëÂû·ÂÀ» Çâ»ó½ÃŰ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ±âÁ¸ÀÇ Ç÷´ç ¸ð´ÏÅ͸µ ±â±â¿Í ºñ±³ÇÏ¿© CGMS´Â ÇǺΠÀ§¿¡ ³õÀ» ¼ö Àֱ⠶§¹®¿¡ Â Çʿ䰡 ¾øÀ¸¸ç, ºü¸£°í °íÅ뽺·´Áö ¾ÊÀº ¹æ½ÄÀ¸·Î ½Ç½Ã°£ Á¤º¸¸¦ Á¦°øÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

¿¬¼ÓÇ÷´çÃøÁ¤½Ã½ºÅÛ(CGMS) ½ÃÀå µ¿Çâ :

CGMS´Â ÀϹÝÀûÀ¸·Î ü³»ÀÇ Æ÷µµ´ç°ú Àν¶¸° ¼öÄ¡¸¦ ÃøÁ¤ÇÏ´Â µ¥ »ç¿ëµÇ¸ç, À§ÇèÇÑ ¼öÁØÀ¸·Î ¶³¾îÁö°Å³ª »ó½ÂÇÏ¸é °æº¸¸¦ ¿ï¸®´Â µ¥ »ç¿ëµÇ¸ç, Àü ¼¼°èÀûÀ¸·Î ´ç´¢º´¿¡ °É¸®±â ½¬¿î ³ëÀÎ Àα¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå Àü¸ÁÀÌ ¹à½À´Ï´Ù. ÀÌ¿¡ µû¶ó ÀúÇ÷´ç ¹× °íÇ÷´ç »óȲÀ» ½Ç½Ã°£À¸·Î ÆÄ¾ÇÇϱâ À§ÇØ Á¦Ç°ÀÌ ³Î¸® »ç¿ëµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ´ç´¢º´ ȯÀÚÀÇ ´çÈ­Ç÷»ö¼Ò(Hb1ac) °ËÃâÀ» Áö¿øÇÏ´Â CGMSÀÇ ´ëÆøÀûÀÎ °³¼±°ú ½Å±â¼úÀÇ ¹ßÀüÀº ½ÃÀå ¼ºÀåÀ» Å©°Ô ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àΰø ÃéÀå ÀåÄ¡ ½Ã½ºÅÛ°ú CGMS ±â¼úÀÇ ÅëÇÕÀ¸·Î ȯÀÚÀÇ Ç÷´çÀ» °ü¸®Çϱâ À§ÇØ Àν¶¸°À» ÆßÇÎÇϰí ÃÖÀûÀÇ ¿ë·®À» Åõ¿©ÇÏ´Â °ÍÀÌ ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î, Æí¸®ÇÑ ´ë¾ÈÀ¸·Î ºñħ½ÀÀû CGMS ÀåÄ¡ÀÇ µµÀÔ, ±¤¹üÀ§ÇÑ Á¶»ç °³¹ß(R&D) Ȱµ¿, Àúħ½ÀÀû ¶Ç´Â ÃÖ¼Ò Ä§½ÀÀû Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ½ÃÀåÀÇ Ãß°¡ ¼ºÀåÀ» À§ÇÑ ¿øµ¿·ÂÀÌ µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼­·Ð

Á¦5Àå ¼¼°èÀÇ ¿¬¼ÓÇ÷´çÃøÁ¤½Ã½ºÅÛ(CGMS) ½ÃÀå

Á¦6Àå ½ÃÀå ºÐ¼® : ÄÄÆ÷³ÍÆ®º°

Á¦7Àå ½ÃÀå ºÐ¼® : Àα¸Åë°èº°

Á¦8Àå ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

Á¦9Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

Á¦10Àå SWOT ºÐ¼®

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå PorterÀÇ Five Forces ºÐ¼®

Á¦13Àå °¡°Ý ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global continuous glucose monitoring systems market size was valued at USD 7.04 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 10.92 Billion by 2033, exhibiting a CAGR of 4.75% from 2025-2033. North America currently dominates the market, holding a market share of over 38.7% in 2024. The increasing awareness and adoption of CGM devices, rising prevalence of diabetes, significant technological advancements in CGM devices, and ongoing shift towards preventive healthcare are some of the factors boosting the continuous glucose monitoring systems market share.

Continuous glucose monitoring systems (CGMS) are technologically advanced devices that automatically track blood glucose levels. They consist of a transmitter-integrated sensor that functions through a transcutaneous or subcutaneous route to continuously measure the glucose concentration in interstitial fluid. The transmitter then sends the information to a wireless monitor that can be clipped to clothes. Continuous glucose monitoring systems assist in providing a complete profile of diabetes, alerting highs and lows of blood sugar levels, detecting patterns, and increasing patient insights regarding physical activity, medication choices, food portions and stress. As compared to conventional glucose monitoring devices, CGMS are prick-free as they can be placed over the skin, thus aiding in providing real-time information in a quick and painless fashion.

Continuous Glucose Monitoring Systems Market Trends:

The rising geriatric population across the globe that are more susceptible to developing diabetes is creating a positive outlook for the market. CGMS is commonly used for measuring glucose and insulin level in the body, which further sounds an alarm if it drops or rises to a dangerous level. In line with this, the widespread product utilization to identify hypoglycemia and hyperglycemic situations in real-time is favoring the market growth. Moreover, significant improvements and new technological advancements in CGMS that aid in detecting glycated hemoglobin (Hb1ac) in patients with diabetes are providing a considerable boost to the market growth. Additionally, the integration of artificial pancreas device systems with CGMS technology to pump insulin and administer optimum dosage to manage the blood sugar levels of patients is positively impacting the market growth. Apart from this, the introduction of non-invasive CGMS devices as a convenient alternative, extensive research and development (R&D) activities and the increasing demand for less or minimally invasive diagnostic tools are anticipated to drive the market further toward growth.

Key Market Segmentation:

Breakup by Component:

Breakup by Demographics:

Breakup by End User:

Breakup by Region:

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being A. Menarini Diagnostics S.r.l., Abbott Laboratories, DexCom Inc., F. Hoffmann-La Roche AG, Glysens Incorporated, LifeScan Inc. (Johnson & Johnson), Medtronic PLC, Medtrum Technologies Inc., Nemaura Medical Inc., Novo Nordisk A/S, Senseonics Holdings Inc. and Waveform Technologies Inc.

Key Questions Answered in This Report

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Continuous Glucose Monitoring Systems Market

6 Market Breakup by Component

7 Market Breakup by Demographics

8 Market Breakup by End User

9 Market Breakup by Region

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â